PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 137 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2014. The put-call ratio across all filers is 1.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $15,000 | -94.3% | 5,256 | +18.4% | 0.00% | -100.0% |
| Q2 2018 | $263,000 | -1.1% | 4,438 | +13.7% | 0.01% | -14.3% |
| Q1 2018 | $266,000 | -31.3% | 3,902 | -0.2% | 0.01% | -30.0% |
| Q4 2017 | $387,000 | -11.6% | 3,910 | +6.9% | 0.01% | -28.6% |
| Q3 2017 | $438,000 | +36.0% | 3,656 | -0.8% | 0.01% | +27.3% |
| Q2 2017 | $322,000 | +50.5% | 3,687 | +35.3% | 0.01% | -57.7% |
| Q4 2015 | $214,000 | -2.7% | 2,726 | -6.8% | 0.03% | +13.0% |
| Q3 2015 | $220,000 | -34.5% | 2,924 | +1.5% | 0.02% | -30.3% |
| Q2 2015 | $336,000 | -42.5% | 2,880 | +16.4% | 0.03% | -53.5% |
| Q1 2015 | $584,000 | +36.1% | 2,474 | +9.1% | 0.07% | +6.0% |
| Q4 2014 | $429,000 | -20.6% | 2,267 | +0.1% | 0.07% | -16.2% |
| Q3 2014 | $540,000 | +116.9% | 2,264 | -5.3% | 0.08% | +86.0% |
| Q1 2014 | $249,000 | +4.6% | 2,391 | +4.1% | 0.04% | +7.5% |
| Q4 2013 | $238,000 | – | 2,296 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 200,000 | $20,706,000 | 6.01% |
| Redmile Group, LLC | 230,673 | $23,882,000 | 2.95% |
| WEATHERBIE CAPITAL, LLC | 241,419 | $24,994,000 | 2.31% |
| Tekla Capital Management LLC | 185,820 | $19,238,000 | 2.02% |
| Ghost Tree Capital, LLC | 25,000 | $2,588,000 | 1.59% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $588,741,000 | 1.56% |
| Iguana Healthcare Management, LLC | 25,000 | $2,588,000 | 1.48% |
| Eventide Asset Management | 42,100 | $4,359,000 | 1.34% |
| Bain Capital Public Equity Management, LLC | 401,330 | $41,550,000 | 1.17% |
| Rock Springs Capital Management LP | 31,500 | $3,261,000 | 1.16% |